Discovering anticancer drug target combinations via network-informed signaling-based approach
Open Access
- 17 October 2025
- journal article
- research article
- Published by Springer Nature in Communications Medicine
- Vol. 5 (1) , 1-17
Abstract
Background Oncologists deciding on cancer treatments must make difficult decisions as to which prescription and implementation strategies would best suit each patient. Much is still unknown about combinations of prescription drugs as there are many to choose from. At the outset, the oncologist reckons with at least two established facts: (i) patients receiving successive single molecules treatments are likely to experience drug resistance, and (ii), to select optimal drug combinations requires to pick the ‘best’ protein drug target combinations. Intuitively, target selection should precede drug selection, implying that well-informed strategies would opt to first consider drug targets — not drugs — combinations. Nowadays, drug combinations that oncologists consider are empirical and limited. They are restricted primarily by observations and praxis, that is, scant clinical experience with their application. Methods Here we develop a strategy for selecting optimal drug target combinations following nature. We use protein-protein interaction networks and shortest paths to discover communication pathways in cells based on interaction network topology. Our strategy mimics cancer signaling in drug resistance, which commonly harnesses pathways parallel to those blocked by drugs, thereby bypassing them. Results We select key communication nodes as combination drug targets inferred from topological features of networks. We test our network-informed signaling-based approach to discover anticancer drug target combinations on available clinical data, patient-derived breast and colorectal cancers. Alpelisib + LJM716 and alpelisib + cetuximab + encorafenib combinations diminish tumors in breast and colorectal cancers, respectively. Conclusions Our network-based approach discovers optimal protein co-target combinations to counter resistance, selecting co-targets from alternative pathways and their connectors.Keywords
This publication has 96 references indexed in Scilit:
- Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast CancersCancer Research, 2013
- Top-Down Network Analysis to Drive Bottom-Up Modeling of Physiological ProcessesJournal of Computational Biology, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Network medicine: a network-based approach to human diseaseNature Reviews Genetics, 2010
- Combining Targeted Therapies: Practical Issues to Consider at the Bench and BedsideThe Oncologist, 2010
- The Importance of Bottlenecks in Protein Networks: Correlation with Gene Essentiality and Expression DynamicsPLOS Computational Biology, 2007
- Global topological features of cancer proteins in the human interactomeBioinformatics, 2006
- The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferationProceedings of the National Academy of Sciences, 2003
- Lethality and centrality in protein networksNature, 2001
- KEGG: Kyoto Encyclopedia of Genes and GenomesNucleic Acids Research, 2000